PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jkmsThis JournalJKMS Journal of Korean Medical ScienceAboutFor Contributorse-Submission
 
J Korean Med Sci. Dec 2002; 17(6): 817–822.
PMCID: PMC3054962
Chemoreduction followed by local therapy and adjuvant chemotherapy for advanced intraocular retinoblastoma: a pilot study in a single center.
Keon Hee Yoo, Woo Yun Sohn, Ki Woong Sung, Hye-Lim Jung, Hong Hoe Koo, Sei Yeul Oh, and Se Woong Kang
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Keon Hee Yoo: hhkoo/at/smc.samsung.co.kr
Abstract
Intraocular (IO) retinoblastoma (RB) has traditionally been treated with enucleation (ENU) or external beam radiotherapy (EBRT). Recently, clinical trials are in progress to cure RB without ENU or EBRT in order to salvage the globe and to avoid unacceptable side effects of EBRT. We performed a pilot study to treat patients with advanced Reese-Ellsworth (RE) stage IO RB with initial chemotherapy (CRx) followed by local therapy (LT) and adjuvant CRx. Ten eyes (8 RE group V, 2 RE group IV) from 9 patients were enrolled from March 2001 to November 2001. All tumors responded to CRx. In 5 of 10 eyes, the RB was enough to be treated with LT after chemoreduction. One patient who underwent LT is waiting for ENU due to post-cryotherapy complication. For a median follow-up of 13 months (8-16 mo), 4 eyes that received LT and adjuvant CRx were relapse-free. A patient with bilateral RB who failed to be a candidate for LT was rescued with high-dose CRx and hematopoietic stem cell transplantation. Consequently, by treating patients according to our strategy, we were able to salvage 6 out of 10 eyes without ENU or EBRT. These results suggest that chemoreduction followed by LT and adjuvant CRx might offer the opportunity to salvage the globe and vision even in patients with advanced stage IO RB.
Articles from Journal of Korean Medical Science are provided here courtesy of
Korean Academy of Medical Sciences